Eric Lefkofsky was born in Michigan in September 1969, and he graduated from the University of Michigan in Ann Arbor with honors in 1991. He later earned a law degree from University of Michigan’s Law School but decided to follow a different passion, technology. Lefkofsky’s internet career began with a company he founded called Starbelly. He later co-founded other companies such as InnerWorkings, Echo Global Logistics, Uptake, Groupon, and Tempus. He is now a wealthy, energetic entrepreneur, but he has also found time to teach at DePaul University’s Graduate School, Northwestern University’s School of Management, and Chicago’s Booth School of Business.
Tempus was co-founded in 2016 by Eric Lefkofsky who also serves as CEO. Tempus technology company the enables physicians to deliver personalized cancer care to their patients. This company is not just another project to Eric especially since his wife Elizabeth was diagnosed with breast cancer. Now Lefkofsky’s determination to make Tempus successful passionate and personal. Tempus collects and analyzes data using statistics and algorithms to give doctors additional information that allows them to develop better treatment plans for patients. The work being done at Tempus allows clinical information about a patient to be electronically compared to molecular information in real-time. This process could potentially allow cancer researchers to develop cures and treatments years sooner than previous thought.
The Lefkofsky’s have a special place in their hearts for cancer care. It is their desire to see cancer cured once and for all. As a result, they have set up the Lefkofsky Family Foundation which gives to numerous cancer researchers. The foundation donated $1 million to Northwestern University’s Robert Lurie Cancer Center, $500,000 to immunotherapy research at Stanford University, $1.2 million to cancer research at University of Michigan, and $250,000 to breast cancer research at New York’s Weill Cornell Medicine for more info about us: http://lefkofskyfoundation.com/about-eric-lefkofsky/ click here.
Eric and Elizabeth Lefkofsky are putting their resources, personally and professionally, behind defeating cancer in their lives and nearly 14.5 million other people in the United States alone.
Few are the people who have set out to work towards something and have ultimately lived their dream. Clay Siegall is one of the few. He has co-founded, Seattle Genetics, the reputable cancer research firm. More so, he holds the company’s helm as the President, Chief Executive Officer and the Chairman of the Board. He has received training as a scientist focusing on targeted cancer treatments. His company is among the leading healthcare research institutions focusing on the formulation of cancer drugs. The institution is built on a solid base of scientific innovation, in-depth research, drug development practices and above all the passion for helping patients.
Under his informed leadership, the company has reached several core milestones in its operations. For starters, the company is leading in the development of Antibody-drug Conjugates (ADC). Moreover, it secured the FDA approval (2011) for its first ADC product. The drug is currently a global brand used in more than 65 countries in the world. Besides, the institution is focused on the advancement of an extensive pipeline of exclusive ADCs for cancer treatment. Again, the firm has joined forces through multiple strategic alliances with different organizations to advance its distinct ADC technology. To the present, these collaborations have generated the firm well over 350 million dollars. On record, more than 20 cancer treatment products utilize the company’s technology that has seen its capital steadily rising to a tune of .2 billion dollars.
Clay Siegall has spanned a highly successful career in the health sector. Prior to Seattle Genetics, he had worked with Bristol-Myers Squibb Pharmaceutical Research Institute. Also, he had served with the National Cancer Institute and National Institutes of Health. Besides, he has rendered directorial services to Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical, a bio-pharmaceutical company focused on developing novel products for rare and ultra-rare diseases. He also serves as a Director on the Board of Mirna Therapeutics, an organization aimed at developing and commercializing microRNA therapeutics.
Clay Siegall’s achievements have been significant. As a result of his dedication to his work and desire to help, he has received numerous recognition and awards including the 2012 Pacific Northwest Ernst &Young Entrepreneur of the Year and also the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He has been a success and has lived his dream to see cancer patients benefit from his efforts.
The fight against cancer is not in any way easy. The lack of high quality and timely treatment is one of the biggest challenges facing many cancer patients, leaving devastating effects on them. Luckily the entrance of Cancer Treatment Centers of America (CTCA) changed everything in the way patients receive treatment and care.
In the Hands of Only the Best
There are five hospitals operating under CTCA, whose headquarters are located in Boca Raton, Florida. They are based in Phoenix, Atlanta, Philadelphia, Tulsa and Chicago and serve not only the area residents but also patients from all over the world. All the CTCA hospitals are staffed by some of the most experienced cancer treatment experts who have at their disposal the most advanced technologies.
Every hospital takes a conventional approach for treatment of cancer including chemotherapy, immunotherapy, and surgery. However, the experts go a step further to deliver supportive therapies in a successful effort to help patients deal with the side-effects related to cancer and its treatment. Above all, every treatment is personalized.
In a bid to provide even better treatment and care to its patients, CTCA struck a partnership with Allscripts and NantHealth. Together, the three entities have succeeded in providing more options for treatment as well as greatly improving efficiency and safety. The partnership involves the use of eviti, a clinical decision support solution by NantHealth, and NantHealth’s Clinical Pathways, a program aimed at reduction of variability and enabling better transparency in selection of therapeutic treatment and care for patients by providing evolving data for cancer care. All the way, the CTCA care standards are adhered to.
The Cancer Treatment Centers of America hospitals are recognized as some of the top-most performers in the fight against cancer. They have received five-star ratings on quality from the United States’ Centers for Medicare and Medicaid Services. In addition, many other healthcare organizations have applauded CTCA for its efforts. They include the National Accreditation Program for Breast Centers (NABPC), American College of Radiology, and Association of Community Cancer Centers. The partnership with Allscripts and NantHealth is sure to greatly improve delivery of treatment and care to CTCA patients as well as move the already high ratings higher.